Market revenue in 2022 | USD 61.4 million |
Market revenue in 2030 | USD 172.5 million |
Growth rate | 13.8% (CAGR from 2022 to 2030) |
Largest segment | Gene panel, ldt & others |
Fastest growing segment | Gene Panel, LDT & Others |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Panel, LDT & Others |
Key market players worldwide | Illumina Inc, Exact Sciences Corp, Foundation Medicine, Guardant Health Inc, Burning Rock Biotech Ltd ADR, Freenome, AnchorDx, GeneCast, Elypta |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to multi cancer early detection market will help companies and investors design strategic landscapes.
gene panel, ldt & others was the largest segment with a revenue share of 100% in 2022. Horizon Databook has segmented the Germany multi cancer early detection market based on gene panel, ldt & others covering the revenue growth of each sub-segment from 2018 to 2030.
In Germany, Merck and Sysmex Inostics were the first to receive CE approval for liquid biopsy tests for patients with colorectal cancer. Furthermore, intense competition between various biotechnology companies, such as Epigenomics and Roche, is expected to boost market growth.
Increasing collaborations between key market players in this region are expected to fuel market growth through increase in research opportunities and development of better test procedures. For instance, in October 2020, Oncocyte entered into a licensing and collaboration agreement with Chronix Biomedical for liquid biopsy technology.
However, high costs of these tests may be a challenge for market growth. Furthermore, in January 2023, Mainz Biomed announced plans to launch a Corporate Health Program in Germany for ColoAlert, a screening test for colorectal cancer.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany multi cancer early detection market , including forecasts for subscribers. This country databook contains high-level insights into Germany multi cancer early detection market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account